Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15588799 | 0.83 | F2 (0.50) | ALDH1A1F2GAAHPGDPOLB | |
| SCHEMBL15588798 | 0.83 | F2 (0.50) | ALDH1A1F2GAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL16766200 | 0.80 | F2 (0.48) | ALDH1A1F2GAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL16766683 | 0.80 | F2 (0.48) | ALDH1A1F2GAAHPGDPOLB | |
| SCHEMBL17336983 | 0.80 | F2 (0.50) | ALDH1A1F2GAAHPGDPOLB | |
| SCHEMBL15588635 | 0.80 | F2 (0.46) | ALDH1A1F2HPGDPOLBHTT | |
| SCHEMBL17186605 | 0.79 | GAA (0.44) | ALDH1A1F2GAAPOLBHTT | |
| SCHEMBL7108628 | 0.78 | CA2 (0.43) | HPGDPOLBCA2CHKAHSD11B1 | |
| Acetic Acid SCHEMBL17417178 | 0.78 | F2 (0.43) | ALDH1A1F2GAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL15560657 | 0.78 | F2 (0.43) | ALDH1A1F2HPGDPOLBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649000-B2 | (2'S,2''R)-4-(2'-(2''-amino-3''-(4'''-ethoxyphenyl)propanoylamino)-3'-phenylpropanoyl-amino)piperidine- 1-carboxamidine; inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation | VANTIA LIMITED (GB) | 2010-01-19 | — | — | US | disclosed |
| EP-1483284-B1 | SELECTIVE DIPEPTIDE INHIBITORS OF KALLIKREIN | FERRING BV (NL) | 2006-07-19 | — | — | EP | disclosed |
| US-20060052313-A1 | Selective dipeptide inhibitors of kallikrein | FERRING B.V | 2006-03-09 | — | — | US | disclosed |
| EP-1483284-A2 | SELECTIVE DIPEPTIDE INHIBITORS OF KALLIKREIN | Ferring BV (NL) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076458-A2 | SELECTIVE DIPEPTIDE INHIBITORS OF KALLIKREIN | FERRING BV (NL) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052313-A1 | Selective dipeptide inhibitors of kallikrein | BDKRB2, BDKRB1, KLKB1 | ALDH1A1 3712/4885F2 108/4885GAA 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.